- Research works
- 36 ▲ 7% vs 2013–17
- Citations
- 1.4k 37.4 per fractional work
- Top-10% rate
- 14.7% record average 16.5%
- Open access
- 37% world 28%
Not ranked overall: Vifor Pharma (Germany) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Health Professions, 5.0×. Every wedge is a field page.
Which keywords describe research at Vifor Pharma (Germany)?
By fractional works in all years, weighted toward what it does more of than the world: Anemia, Iron Deficiency, Inflammation, Heart Failure, Chronic Kidney Disease, Oxidative Stress, Cardiovascular Disease and Hepcidin.
- Cancer
- Bacterial Therapy
- Tumor Microenvironment
- Sickle-cell Disease
- Metastasis
- Angiogenesis
- Pulmonary Hypertension
- Gene Therapy
- Diagnosis
- Fc Receptors
- Glycosylation
- Erythropoiesis-Stimulating Agents
- Neuroprotection
- Iron Regulation
- Cardiovascular Disease
- Chronic Kidney Disease
- Heart Failure
- Inflammation
- Anemia
- Iron Deficiency
- Oxidative Stress
- Epidemiology
- Hepcidin
- Immunotherapy
- Cancer Treatment
- Hypoxia-Inducible Factors
- Treatment
- Therapeutic Antibodies
- Immune Response
- Ion Channels
- Tumor Suppression
- Hyperkalemia
- Renin-Angiotensin-Aldosterone System Inhibitors
- Thalassemia
- Tumor Regression
- Tumor Targeting
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 36 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 36 words, with their numbers
- Anemia6▲ 134×4 topics
- Inflammation5▲ 6.3×12 topics
- Iron Deficiency5▲ 262×2 topics
- Heart Failure4▲ 26×4 topics
- Oxidative Stress4▲ 6.5×7 topics
- Chronic Kidney Disease4▲ 45×5 topics
- Epidemiology4▲ 2.8×15 topics
- Cardiovascular Disease4▲ 9.7×8 topics
- Hepcidin3▲ 207×1 topic
- Iron Regulation3▲ 207×1 topic
- Immunotherapy2▲ 10×5 topics
- Neuroprotection2▲ 18×3 topics
- Cancer Treatment2▲ 24×2 topics
- Erythropoiesis-Stimulating Agents2▲ 422×1 topic
- Hypoxia-Inducible Factors2▲ 422×1 topic
- Glycosylation2▲ 24×2 topics
- Treatment2▲ 3.7×7 topics
- Fc Receptors2▲ 43×1 topic
- Therapeutic Antibodies2▲ 34×1 topic
- Diagnosis1▲ 3.7×4 topics
- Immune Response1▲ 6.1×4 topics
- Gene Therapy1▲ 13×3 topics
- Ion Channels1▲ 16×2 topics
- Pulmonary Hypertension1▲ 22×2 topics
- Tumor Suppression1▲ 32×2 topics
- Angiogenesis1▲ 8.4×2 topics
- Hyperkalemia1▲ 234×1 topic
- Metastasis1▲ 10×2 topics
- Renin-Angiotensin-Aldosterone System Inhibitors1▲ 234×1 topic
- Sickle-cell Disease1▲ 70×1 topic
- Thalassemia1▲ 70×1 topic
- Tumor Microenvironment1▲ 9.4×2 topics
- Tumor Regression1▲ 39×2 topics
- Bacterial Therapy1▲ 67×1 topic
- Tumor Targeting1▲ 22×1 topic
- Cancer1▲ 2.0×8 topics
Which research topics does Vifor Pharma (Germany) publish most on?
By volume in 2022–2025: Renal Diseases and Glomerulopathies, Health and Medical Studies, Platelet Disorders and Treatments and Chronic Kidney Disease and Diabetes.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Renal Diseases and Glomerulopathies Nephrology 1 works
- 2 Health and Medical Studies General Health Professions 0 works
- 3 Platelet Disorders and Treatments Hematology 0 works
- 4 Chronic Kidney Disease and Diabetes Nephrology 0 works
- 5 Myasthenia Gravis and Thymoma Neurology 0 works
- 6 Dermatology and Skin Diseases Dermatology 0 works
- 7 Medical Practices and Rehabilitation Physical Therapy, Sports Therapy and Rehabilitation 0 works
- 8 Complement system in diseases Immunology 0 works
- 9 Medical and Health Sciences Research Public Health, Environmental and Occupational Health 0 works
- 10 Systemic Sclerosis and Related Diseases Pathology and Forensic Medicine 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Vifor Pharma (Germany)'s research output changed?
Output in 2018–2022 was 7% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Munich
- Ludwig-Maximilians-Universität München
- Max Planck Society
- Technical University of Munich
- Siemens (Germany)
- München Klinik
- LMU Klinikum
- Munich University of Applied Sciences
- TUM Klinikum
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.